Russell Investments Group Ltd. Sells 34,989 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Russell Investments Group Ltd. trimmed its stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 60.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,316 shares of the company's stock after selling 34,989 shares during the quarter. Russell Investments Group Ltd. owned 0.06% of SI-BONE worth $327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. FMR LLC boosted its holdings in SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after purchasing an additional 1,198 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of SI-BONE by 29.0% during the 3rd quarter. Jane Street Group LLC now owns 77,359 shares of the company's stock valued at $1,081,000 after acquiring an additional 17,410 shares during the last quarter. Barclays PLC raised its stake in shares of SI-BONE by 190.8% in the 3rd quarter. Barclays PLC now owns 96,623 shares of the company's stock valued at $1,350,000 after acquiring an additional 63,402 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of SI-BONE by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 924,044 shares of the company's stock valued at $12,921,000 after acquiring an additional 30,005 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in SI-BONE by 9.4% in the 3rd quarter. Franklin Resources Inc. now owns 20,220 shares of the company's stock worth $265,000 after purchasing an additional 1,745 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at SI-BONE

In other SI-BONE news, SVP Michael A. Pisetsky sold 3,128 shares of SI-BONE stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the sale, the senior vice president now owns 244,878 shares in the company, valued at $3,462,574.92. The trade was a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Anthony J. Recupero sold 3,311 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total transaction of $46,850.65. Following the completion of the transaction, the insider now owns 284,555 shares of the company's stock, valued at approximately $4,026,453.25. This represents a 1.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,776 shares of company stock valued at $96,644. 3.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of SI-BONE in a research report on Tuesday, February 25th. Needham & Company LLC boosted their target price on shares of SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Finally, Truist Financial restated a "buy" rating and set a $22.00 price target (up from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $24.40.

SI-BONE Stock Performance

NASDAQ:SIBN traded up $0.06 during trading hours on Monday, hitting $14.47. 277,689 shares of the company traded hands, compared to its average volume of 360,732. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $614.29 million, a price-to-earnings ratio of -15.73 and a beta of 1.02. The firm has a 50-day moving average of $15.00 and a 200 day moving average of $14.65. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $19.16.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The business had revenue of $49.00 million during the quarter, compared to analysts' expectations of $48.87 million. On average, analysts forecast that SI-BONE, Inc. will post -0.78 EPS for the current year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.